Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Geelen

Showing results (71-80 of 85) with videos related to

Pageof 9
Sort By:
International Journal of Cardiology|September 4, 2020
Heart failure with preserved ejection fraction or non-cardiac dyspnea in paroxysmal atrial fibrillation: The role of left atrial strainA Katbeh, T De Potter, P Geelen, et al.
Haematologica|September 2, 2017
Treatment outcome in a population-based, 'real-world' cohort of patients with chronic myeloid leukemiaInge G P Geelen, Noortje Thielen, Jeroen J W M Janssen, et al.
European Journal of Haematology|December 31, 2017
Omitting cytogenetic assessment from routine treatment response monitoring in chronic myeloid leukemia is safeInge G P Geelen, Noortje Thielen, Jeroen J W M Janssen, et al.
Haematologica|March 23, 2023
High-risk additional cytogenetic aberrations in a Dutch chronic phase chronic myeloid leukemia patient populationCamille C B Kockerols, Inge G P Geelen, Mark-David Levin, et al.
Antimicrobial Agents and Chemotherapy|February 22, 2001
Pharmacokinetics of the protease inhibitor indinavir in human immunodeficiency virus type 1-infected childrenD M Burger, A M van Rossum, P W Hugen, et al.
The Pediatric Infectious Disease Journal|August 23, 2002
Therapeutic drug monitoring of indinavir and nelfinavir to assess adherence to therapy in human immunodeficiency virus-infected childrenAnnemarie M van Rossum, Alina S Bergshoeff, Pieter L Fraaij, et al.
Haematologica|September 2, 2017
Impact of hospital experience on the quality of tyrosine kinase inhibitor response monitoring and consequence for chronic myeloid leukemia patient survivalInge G P Geelen, Noortje Thielen, Jeroen J W M Janssen, et al.
Leukemia & Lymphoma|November 6, 2020
Tyrosine kinase inhibitor treatment discontinuation in chronic myeloid leukemia: patient viewsVashti N M F Tromp, Lonneke Timmers, Leanne Koningen, et al.
British Journal of Haematology|July 12, 2020
Blood cell counts and lymphocyte subsets of patients admitted during the COVID-19 pandemic: a prospective cohort studyPaul J Hengeveld, Aaram O Khader, Linda H A de Bruin, et al.
AIDS Research and Treatment|March 9, 2012
Barriers to Initiation of Pediatric HIV Treatment in Uganda: A Mixed-Method StudyT Sonia Boender, Kim C E Sigaloff, Joshua Kayiwa, et al.
Pageof 9

Showing results (71-80 of 85) with videos related to

Sort By:
Pageof 9
International Journal of Cardiology|September 4, 2020
Heart failure with preserved ejection fraction or non-cardiac dyspnea in paroxysmal atrial fibrillation: The role of left atrial strainA Katbeh, T De Potter, P Geelen, et al.
Haematologica|September 2, 2017
Treatment outcome in a population-based, 'real-world' cohort of patients with chronic myeloid leukemiaInge G P Geelen, Noortje Thielen, Jeroen J W M Janssen, et al.
European Journal of Haematology|December 31, 2017
Omitting cytogenetic assessment from routine treatment response monitoring in chronic myeloid leukemia is safeInge G P Geelen, Noortje Thielen, Jeroen J W M Janssen, et al.
Haematologica|March 23, 2023
High-risk additional cytogenetic aberrations in a Dutch chronic phase chronic myeloid leukemia patient populationCamille C B Kockerols, Inge G P Geelen, Mark-David Levin, et al.
Antimicrobial Agents and Chemotherapy|February 22, 2001
Pharmacokinetics of the protease inhibitor indinavir in human immunodeficiency virus type 1-infected childrenD M Burger, A M van Rossum, P W Hugen, et al.
The Pediatric Infectious Disease Journal|August 23, 2002
Therapeutic drug monitoring of indinavir and nelfinavir to assess adherence to therapy in human immunodeficiency virus-infected childrenAnnemarie M van Rossum, Alina S Bergshoeff, Pieter L Fraaij, et al.
Haematologica|September 2, 2017
Impact of hospital experience on the quality of tyrosine kinase inhibitor response monitoring and consequence for chronic myeloid leukemia patient survivalInge G P Geelen, Noortje Thielen, Jeroen J W M Janssen, et al.
Leukemia & Lymphoma|November 6, 2020
Tyrosine kinase inhibitor treatment discontinuation in chronic myeloid leukemia: patient viewsVashti N M F Tromp, Lonneke Timmers, Leanne Koningen, et al.
British Journal of Haematology|July 12, 2020
Blood cell counts and lymphocyte subsets of patients admitted during the COVID-19 pandemic: a prospective cohort studyPaul J Hengeveld, Aaram O Khader, Linda H A de Bruin, et al.
AIDS Research and Treatment|March 9, 2012
Barriers to Initiation of Pediatric HIV Treatment in Uganda: A Mixed-Method StudyT Sonia Boender, Kim C E Sigaloff, Joshua Kayiwa, et al.
Pageof 9